<DOC>
	<DOCNO>NCT01849068</DOCNO>
	<brief_summary>Ezetimibe show inhibit cholesterol absorption several line evidence vitro system animal model suggest effect associate increase low-density lipoprotein ( LDL ) receptor expression small intestine . The impact treatment ezetimibe intestinal gene expression protein mass level LDL receptor key gene involve intestinal cholesterol homeostasis examine dyslipidemic men insulin-resistance . In present study , gene expression study protein mass level assess duodenal biopsy real-time polymerase chain reaction ( rt-PCR ) liquid chromatography-mass spectrometry ( LC-MS/MS ) , respectively . The primary objective proposal examine effect ezetimibe intestinal gene expression ( rt-PCR ) protein mass level ( LC-MS/MS ) LDL receptor dyslipidemic men insulin-resistance . The secondary objective examine impact ezetimibe treatment intestinal gene expression protein mass level sterol regulatory element-binding protein ( SREBP ) -2 , Niemann-Pick C1-Like1 ( NPC1L1 ) , ATP bind cassette gene ( ABCG ) -5/8 , proprotein convertase subtilisin/kexin type 9 ( PCSK9 ) 3-hydroxy-3-methyl-glutaryl-CoA ( HMG CoA ) reductase . Primary hypothesis Treatment ezetimibe 10 mg/day significantly increase duodenal mRNA protein mass level LDL receptor dyslipidemic men insulin-resistance . Secondary hypothesis Treatment ezetimibe 10 mg/day significantly increase duodenal mRNA protein mass level SREBP-2 , NPC1L1 , ABCG5/8 , PCSK9 HMG CoA reductase dyslipidemic men insulin-resistance .</brief_summary>
	<brief_title>Effects Selective Inhibition Cholesterol Absorption With Ezetimibe Intestinal Cholesterol Homeostasis Dyslipidemic Men With Insulin-resistance - Pilot Study</brief_title>
	<detailed_description />
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Men age 1860 year Waist circumference &gt; 102 cm HDLcholesterol &lt; 1.1 mmol/L Triglycerides &gt; 1.7 mmol/L Fasting blood glucose &gt; 6.1 mmol/L Normal blood pressure ( &lt; 130/85 ) Women Men &lt; 18 &gt; 60 year Smokers ( &gt; 1 cigarette/day ) Body weight variation &gt; 10 % last 6 month prior study baseline Subjects previous history cardiovascular disease Subjects type 2 diabetes Subjects monogenic dyslipidemia Subjects hypertension medication medication know affect lipoprotein metabolism integrity gastrointestinal mucosa Subjects endocrine gastrointestinal disorder History alcohol drug abuse within past 2 year Subjects situation condition , opinion investigator , may interfere optimal participation study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>